NDATOPICALGEL
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BENZAMYCIN (erythromycin and benzoyl peroxide) by Bausch + Lomb is clinical pharmacology the exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. First approved in 1984.
Drug data last refreshed 15h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benzamycin is a fixed-dose topical gel combining erythromycin (antibiotic) and benzoyl peroxide (keratolytic agent) for the treatment of acne vulgaris. Erythromycin reduces lesions through antibacterial activity, while benzoyl peroxide provides keratolytic and desquamative effects. The synergistic combination targets both bacterial and inflammatory components of acne.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating contracting commercial teams and defensive portfolio strategy.
Mechanism of Action
CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Benzamycin offers limited career growth opportunity given its LOE-approaching status and minimal linked job postings. Roles on this product focus on defending market share, managing generic transition, and optimizing profitability rather than driving new patient acquisition.
Brand Manager
Worked on BENZAMYCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.